WILEX AG : PR: FDA grants Fast Track designation to WILEX's RENCAREX® for the ... - 4-traders (press release) PDF Print
4-traders (press release)
No drug has been approved to date by the FDA or EMA for the adjuvant therapy of non-metastatic clear cell renal cell carcinoma. RENCAREX® was granted Orphan Drug status in the USA and in Europe and is of major relevance for those patients with this

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.